Long-term prognosis of haemangioblastoma of the CNS: Impact of von Hippel-Lindau disease by Niemelä, M. et al.
Long-Term Prognosis of Haemangioblastoma of the CNS: Impact of von
Hippel-Lindau Disease
M. NiemelaÈ1, S. Lemeta2, P. Summanen3, T. BoÈhling4, M. Sainio5, J. Kere6, K. Poussa7, R. Sankila8,
H. Haapasalo9, H. KaÈaÈriaÈinen6, E. Pukkala10, and J. JaÈaÈskelaÈinen1
1Department of Neurosurgery, Helsinki University Hospital, Helsinki, Finland
2Department of Neurology, Helsinki University Hospital, Helsinki, Finland
3Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland
4Department of Pathology, Helsinki University Hospital, Helsinki, Finland
5 Institute of Occupational Health, Helsinki, Finland
6Department of Medical Genetics, Helsinki University Hospital, Helsinki, Finland
7Department of Radiology, Helsinki University Hospital, Helsinki, Finland
8 International Agency for Research on Cancer, Lyon, France
9Department of Pathology, Tampere University Hospital, Tampere, Finland
10Finnish Cancer Registry, Helsinki, Finland
Summary
The aim was to assess the frequency of von Hippel-Lindau disease
(VHL) and the long-term prognosis of VHL and non-VHL patients
among 110 consecutive patients with haemangioblastoma (HB) of
the CNS treated between 1953 and 1993 at one neurosurgical unit.
To reveal VHL manifestations we performed a detailed clinical
and radiological examination (neuraxis and abdomen) (61/110),
VHL-gene mutation analysis (40/110), and collection of all available
clinical, imaging, operative and autopsy data from the hospitals in-
volved. All patients were followed-up with a median of 14 years (ex-
cluding 14 operative deaths), and no patient was lost to follow-up.
Altogether 49 patients died during the follow-up.
In the 14 VHL patients (13%), HB(s) of the CNS were detected at
a median age of 33 years, retinal HB(s) at 39 years, and renal cell
carcinoma (RCC) at 43 years. The frequency of VHL in patients
operated on for HB(s) was 29% before the age of 25 years, 19% be-
tween 25 and 45 years, and only 2% after 45 years. HB patients not
meeting the VHL criteria had internal organ cysts in 14%. One non-
VHL patient (4%) had two adjacent HBs in the same cyst wall. The
growth rates of non-VHL and VHL-related HBs were similar as in-
dicated by the median time to recurrence and the proliferation indi-
ces (MIB-1). Recurrence of the HB in patients whose primary oper-
ation was considered radical developed in four of the 10 VHL
patients at a median of 19 years, and in nine of the 74 non-VHL pa-
tients at a median of 11 years. The median length of life of all VHL
and non-VHL patients was 46 and 63 years, respectively. In VHL,
RCC and HBs were equal causes of death.
Keywords: Haemangioblastoma; von Hippel-Lindau disease; sur-
gery; survival.
Introduction
Von Hippel-Lindau disease (VHL) is a rare (1/
36 000 live births) dominantly inherited cancer syn-
drome predisposing to multiple haemangioblastomas
(HB) of the CNS and retina, renal cell carcinomas
(RCC), pancreatic carcinoma, pheochromocytomas,
and cysts in the kidneys, liver, and pancreas [10, 13, 14,
24, 25, 32, 33, 35, 39, 41, 49, 51]. VHL is caused by a
defect in the VHL tumour suppressor gene in chro-
mosome 3p25±p26 [22]. The penetrance is high as al-
most 100% of carriers of a VHL gene defect will de-
velop clinical manifestations by the age of 60 years
[35], and so their children have a 50% risk of getting
the disease. VHL clearly reduces the length of life as
the mean age at death is 40 to 50 years [31]. Due to
advances in microsurgery, RCC has exceeded HBs of
the CNS as the leading cause of death in VHL [26].
The HB is a highly vascular, benign and well-
circumscribed, slowly growing solid or cystic neoplasm
of the CNS and retina composed of stromal cells, en-
dothelial cells, pericytes, and mast cells. The origin of
the stromal cells, believed to be the true neoplastic cells
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ycythaemia by secreting erythropoietin from stromal
or mast cells [3]. HB of the CNS is regarded to be spo-
radic in 60±90% of cases [1, 28, 34, 40] and then it is
typically a single, cystic lesion of the cerebellum, brain
stem or upper cervical medulla, presenting at the
average age of somewhat over 40 years [27]. Multiple
HBs are a typical manifestation of von Hippel-Lindau
disease (VHL) in which HBs of the CNS occur about
10 years earlier than their sporadic counterparts [26,
41]. HB of the retina originates from the inner, mid-
peripheral retina, and is histologically identical to HB
of the CNS [16, 50, 51, 52]. Retinal HB is the ®rst
manifestation in about half of the VHL patients, and is
usually bilateral and multifocal or becomes so over the
years [28, 35, 51]. The mean age at presentation is 25
years [21, 28, 31, 35, 52]. There are sporadic retinal
HBs without VHL [50], but their prevalence still re-
mains unde®ned.
Long-term follow-up data of unselected HBs of the
CNS treated with population responsibility are scarce.
This study assessed the occurrence of VHL-associated
manifestations, and the long-term outcome of VHL
and non-VHL patients in a series of 110 patients with
HB(s) of the CNS treated at one neurosurgical unit.
Methods and Patients
Patients and Haemangioblastomas
The ®les of the Department of Neurosurgery, Helsinki University
Hospital, a unit with population responsibility, revealed 110 consec-
utive HB patients ful®lling the following criteria:
a. Primary operation for HB(s) of the CNS between 1953 and 1993.
b. Histological veri®cation of the solid part.
c. HB ascertained at histological re-examination by a neuro-
pathologist (TB).
Follow-up Data
All available clinical data were collected to ®nd out the occurrence
of VHL manifestations in these 110 HB patients (50 males, 60 fe-
males). The records of the Department of Neurosurgery and all other
hospitals involved were surveyed for clinical, imaging, operative and
autopsy evidence of VHL. The addresses and the death certi®cates of
the patients were obtained from the Population Register Centre of
Finland and the Statistics Finland. A detailed inquiry was sent to
patients before the follow-up examination concerning all their ill-
nesses, hospital admissions and operations. The follow-up time
started at the date of the primary operation and ended at death
(49 110 patients) or on August 31, 1998. No patient was lost to
follow-up.
Clinical Examination
A detailed clinical examination to reveal signs of VHL was per-
formed between 1991 and 1998 in 61 of the 66 (92%) live patients.
This included family history for VHL, a physical and neurological
examination (MN), ophthalmological examination (PS) including
indirect ophthalmoscopy and Goldmann 3-mirror contact lens fun-
dus examination, enhanced MRI scan (1.0 T) of the head and upper
cervical spine, and enhanced CT scan of the upper abdomen (kid-
neys, adrenals, liver and pancreas).
Family Pedigrees and Finnish Cancer Registry
Detailed pedigrees with ®rst and second degree relatives were
constructed for 35 HB patients with at least some data suggestive of
VHL, using the ®les of the Population Register Centre and the parish
records. These 35 patients with their 471 relatives were linked with
the ®les of the Finnish Cancer Registry (FCR) to ®nd VHL related
neoplasms (HB of the CNS, RCC, pancreatic carcinoma, pheo-
chromocytoma). The population-based nationwide FCR has func-
tioned since 1953. All hospitals, health care centers, physicians, and
pathological laboratories are requested to notify FCR of all cancer
cases (benign and malignant CNS tumours included) that come to
their attention, and FCR also receives information of all death cer-
ti®cates with a cancer diagnosis: over 99% of the 63 722 solid tu-
mours diagnosed in Finland between 1985 to 1988 were recorded at
FCR [47]. Furthermore, everybody living in Finland has had a 11-
digit personal identi®cation code since 1967 allowing complete fol-
low-up of every person for death and emigration, and also linking of
registry data.
Mutation Analysis
Germ-line mutations of the VHL gene were analysed by direct
sequencing from all live patients with clinically clear VHL [4], sus-
pect patients with HB and internal organ cyst(s) [11], and also in
25 apparently sporadic HB patients (Table 1). High molecular
weight DNA was extracted from peripheral blood leucocytes by the
QiA Amp Blood kit (QiAGEN Ltd., Cambridge, UK). The three
exons of the VHL gene (coding region of 852 nucleotides) were
sequenced, including the exon splice sites. The primers and the
PCR conditions (with slight modi®cation) were as described else-
where [7]. We also used a reverse primer for the exon 1, SS1,
5 0GCGGTAGAGGGGCTTCAGACCGTG-3 0. PCR products
were puri®ed with the QiA quick PCR puri®cation kit (Qiagen, Hil-
den, Germany), and the sequencing reactions were done using the
ABI PRISM DYE Terminator sequencing kit (Perkin-Elmer Ap-
plied Biosystems Division, Foster City, CA), and were analysed on
the ABI 373 A sequencer. Both strands were sequenced.
VHL Criteria
Clinically, a patient with multiple HBs of the CNS with or without
family history of VHL, or a patient having HB(s) of the CNS to-
gether with one of the following lesions was considered as having
VHL: HB of the CNS, RCC, pancreatic carcinoma or pheochromo-
cytoma [9, 28, 30, 31].
Proliferation Potential
Proliferation by MIB-1 (Ki-67) labelling could be studied in 39 of
the primary 87 HBs operated on between 1968 and 1993, and in 11
recurrences and second tumours of these patients. Brie¯y, mono-
clonal antibody MIB-1 (IgG, Immunotech, Marseille, France) was
used on depara½nised and rehydrated tissue sections. Sections were
treated in a microwave oven and the primary antibody was vi-
sualized with a streptavidin-biotin technique (Zymed Laboratories,
CA) [42]. Proliferation index (MIB-1 index) is the percentage of im-
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munopositive tumour cell nuclei among at least 500 neoplastic nuclei
[17].
Statistical Methods
Median and range were used to describe distributions, and the
Mann-Whitney or Kruskal-Wallis tests to compare groups.
Results
Distinction of VHL and Non-VHL Patients
All available clinical data gathered during the me-
dian follow-up time of 14 years (range 0.3±36 years)
together with a detailed clinical examination (61/110
patients), family history (93/110 patients), detailed
pedigree (35/110 patients), mutation analysis (40/110
patients) and linkage to the ®les of FCR (35 HB pa-
tients and 471 relatives) led to the distinction of three
di¨erent patient groups: (a) 14 VHL patients; (b) 13
patients with a single HB and visceral cyst(s) but no
other VHL manifestations; and (c) 93 apparently spo-
radic HB patients (Table 1). The linkage of HB pa-
tients and their relatives to the FCR ®les to ®nd out
VHL-related tumours did not disclose new families.
The mutation analysis could be performed in 4 VHL
patients, in 11 patients with a single HB and visceral
cyst(s), and in 25 patients with a sporadic HB. The
analysis revealed a missense mutation in two of the
four VHL patients studied, but in none of the other 36
patients.
Exclusion of VHL was less certain in the 14 patients
who died within three months after the primary oper-
ation, mostly in the early years. The median age at
surgery was 55 years (range 24±68 years). According
to the clinical data, all 14 were considered to be free of
VHL. Only one of the deaths occurred during the last
10 years (1/26) after a partial removal of a brain stem
HB.
Table 1. Characteristics of 14 VHL and 96 Non-VHL Patients Operated on for HB(s) of the CNS (Median Values Given)





Number of patients 14 13 83
Sex M/F 5/9 7/6 38/45
Retinal HBs 8/14 0 0
RCC 10/14 0 0
Visceral cysts 8/14 13/13 0
First removal of HB












Cerebellum 10 (71%) 11 (85%) 73 (86%)
Brain stem 3 1 3
Spinal 0 1 4
Supratentorial 1 0 3
Adjoining cyst 9/14 (64%) 9/13 (69%) 60/83 (72%)
Diameter of the solid part in mm
(range)
22 (10±46) n  8 23 (6±39) n  11 20 (4±45) n  38
Extent of removal
Complete 10 (71%) 12 (92%) 74 (89%)
Partial 4 0 5
Biopsy 0 1 4
Operative deaths (<3 months) 0 1 13
Long-term follow-up (>2 years)
Number of patients 12 12 64
Recurrence after complete removal 4/10 0/11 9/59
Time to recurrence in years (range) 19 (2±25) 11 (3±35) 0.88 Mann-Whitney
MIB-1 of available HBs 0.3% n  9 0.2% n  4 0.2% n  37
Follow-up time in years (range) 16 (4±26) 13 (4±25) 16 (2±36)
Death 11/12 1/12 18/64
Age at death in years (range) HB 47 (46±51) n  3 66 (55±81) n  6 0.02 Mann-Whitney
RCC 49 (26±66) n  5
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Characteristics of VHL Patients
Of the unrelated 14 VHL patients (®ve males, nine
females), six (43%) had family history of VHL, and
eight apparently had a new mutation. The frequency
of VHL in patients operated on for HB(s) of the CNS
was 31% (4/13) before the age of 25, 19% (9/48) be-
tween 25 and 45 years, and only 2% (1/49) after 45
years. In 11 of the 14 VHL patients (79%), HB(s) of the
CNS was the ®rst manifestation of the disease. Multi-
ple HBs of the CNS were detected in 10 patients (Fig.
1) and a single one in four, retinal HBs in eight patients
(5/8 bilateral), RCC in 10 patients (6/10 bilateral) (Fig.
2), and pheochromocytoma in two patients (one bilat-
eral), pancreatic carcinoma in one patient, bilateral
renal cysts in eight patients, and pancreatic cysts in
three patients. No liver cysts were encountered. In the
14 VHL patients, the median age at the ®rst operation
for HB(s) of the CNS was 33 (18±50) years, sig-
ni®cantly p  0:005 less than the 45 (16±79) years in
the 96 non-VHL patients (45 males, 51 females). The
median age at the detection of retinal HB(s) was 39
(19±65) years. RCC was detected in 10 VHL (67%)
patients (two at autopsy) at a median age of 43 (26±57)
years, and at a median interval of 11 (0.1±25) years
from the ®rst operation for HB(s).
HB of the CNS
The site of the HB(s) di¨ered between VHL and
non-VHL patients (Fig. 3): half of the 14 VHL patients
had brainstem (Fig. 4) or spinal (Figs. 5 and 6) HB(s)
at some stage, and only 5% (5/96) and 4% (4/96) of the
non-VHL patients had a single HB in either of these
two locations. Two of the 14 (14%) VHL patients and
three of the 96 (3%) non-VHL patients had a supra-
tentorial HB. One patient had two adjacent HBs in the
same cyst wall removed at the age of 38 years. How-
ever, negative family history, the lack of other VHL
manifestations by the age of 58 years, and no germ-line
mutation of the VHL gene together suggest that the
adjacent HBs were not VHL-associated. Recurrence of
an HB in the original operation area developed in four
Fig. 1. MRI scan of two small solid cerebellar HBs (arrows) in a 52-
year-old VHL patient
Fig. 2. Abdominal CT scan of a 64-year-old VHL patient with the
right kidney removed because of RCC. In the left kidney there are
RCC (a) and cysts (b)
Fig. 3. MRI scan of a typical cystic cerebellar HB in a 39-year-old
non-VHL patient
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of the 10 VHL patients whose primary operation was
considered to be radical, at two, 16, 21 and 25 years
(median 19 years), and in nine of the 74 non-VHL pa-
tients (Fig. 7) at a median of 11 (3±35) years. The time
to recurrence did not di¨er between VHL and non-
VHL patients, suggesting a similar growth rate of HBs
in both groups, in agreement with low MIB-1 labelling
indices (0.3% for 9 VHL tumors vs. 0.2% for 41 non-
VHL tumours).
HB of the Retina
We performed a detailed ophthalmological exami-
nation of 60 of the 110 patients, and another 35 pa-
tients had had ophthalmoscopy earlier during the
follow-up. No ophthalmological data was avail-
able for 15 patients. Retinal HBs (Fig. 8) were detected
in (eight patients, and two of them had retinal HBs
Fig. 4. Two solid brain stem HBs and a cys-
tic HB in the cervical spine in a 32-year-old
VHL patient
Fig. 5. An HB in cervical spine in a 21 year-old VHL patient: MRI with contrast (a), superselective angiography before (b) and after (c) pre-
operative embolization
Fig. 6. Two small spinal HBs in the thoracic region (a and b) in the
same patient as in Figure 5 three years later
Long-Term Prognosis of Haemangioblastoma of the CNS 1151
as their ®rst VHL manifestation. Four patients had
visual disturbances, and four were asymptomatic
at detection. When a patient had HBs both of the
CNS and the retina, there were always other VHL
manifestations present.
Cysts of Internal Organs
In 11 of the 14 VHL patients, the upper abdomen
was studied by CT, ultrasound, surgery or autopsy,
and cysts were found in eight patients. None of the
cysts were the sole indication for surgical intervention.
There were 13 patients with a single HB and asympto-
matic cyst(s) of internal organs. The median age of 56
years at the ®rst HB operation, the lack of other VHL-
associated manifestations, negative family history, and
no germ-line mutations of the VHL gene (11 patients
studied) together suggest that the internal organ cyst(s)
in these 13 patients were incidental ®ndings. The
cyst(s) occurred in the kidney(s) in 10 patients (three
bilateral), in the liver in four patients, in the pancreas
in two patients, and in the spleen in one patient. The
abdominal organs of 60 patients, regarded to be free of
VHL, were imaged by CT (54 patients) or ultra sound
(six patients), and incidental cysts were found in 17%
(10/60) in the kidneys, 7% in the liver (4/60), and 3%
(2/60) in the pancreas.
Long-Term Survival of VHL and Non-VHL Patients
A total of 12 of the 14 VHL patients survived at least
two years after the primary HB operation. The median
follow-up time for these 12 patients was 16 (4±26)
years, and during the follow-up nine of them died at a
median age of 47 (26±66) years. All died of the disease,
®ve of RCC at a median of 49 (26±66) years, three of
HB(s) at a median age of 47 (46±51) years, and one of
pancreatic carcinoma at 45 years.
A total of 70 of the 96 non-VHL patients survived
more than two years after the primary radical HB re-
moval. During the median follow-up time of 16 years
(range 2±36 years), 18 patients died at the median age
of 65 years (range 51±81 years). There were six deaths
due to recurrence of the HB at the original operation
site after a median of 15 years (range 3±35 years) at the
median age of 66 years (range 55±81), and 12 non-
related deaths at the median of 65 years (range 51±77).
Discussion
The Prevalence of VHL in HB Patients
The prevalence of VHL is at least 13% in this un-
selected and population-based series of 110 patients
operated on for HBs of the CNS, which appears to be
an underestimation when compared to recent studies
[1, 27, 34, 39, 41], showing prevalence of up to 40%.
Our series was retrospective spanning over four deca-
des, and characterized by high operative mortality in
the early years. On the other hand, the follow-up time
was long and all available data were collected to detect
the cases of VHL: 61 live patients were studied clini-
cally in detail, eight patients had clearly developed
VHL, in 17 patients autopsy excluded VHL, and 12
patients reached the age of 65 years or more without
Fig. 7. A large solid recurrent HB 11 years after the primary total
removal in a 66-year-old non-VHL patient
Fig. 8. Ophthalmoscopic view before treatment of a typical retinal
HB with draining vessels
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signs of VHL. This left 13 patients with data insu½-
cient to rule out VHL.
Detection of VHL Manifestations
All patients with HB(s) of the CNS should be
screened for VHL by MRI of the brain and spinal
cord, ophthalmoscopy, abdominal CT or MRI, and by
obtaining the family history. Early detection of inci-
dental HB(s) of the CNS may be more favourable at
least in terms of radiosurgery [6, 37]. When retinal HBs
are small and asymptomatic they are easier to treat
with laser or cryocoagulation, and the prognosis of
vision is better [52]. The prognosis of RCC is probably
also better with early detection [15, 36, 45]. In our
series, VHL-related HB(s) were detected at a median
age of 33 years, in accordance with earlier studies [35,
39]. Retinal HBs were diagnosed at the median age
of 39 years in contrast to the 25 years in VHL-based
series [35, 51]. RCC was detected at a median age of
43 years, somewhat later than the 33 years in a recent
series [35].
Lesions Suggestive of VHL
The lesions detected in VHL may also occur inci-
dentally in otherwise healthy subjects, but typically at
an older age than in VHL patients [35, 39]. Multiple
HBs of the CNS are considered as a classical sign of
VHL. In our series, one non-VHL patient (1%) had
two HB nodules in the same cyst wall at the primary
removal. Negative family history and no germ-line
mutation found together with the lack of other VHL
manifestations during the long follow-up suggest that
this patient did not have VHL. Multiple HBs may still
represent mosaicism or segmental VHL, negative
family history explained by mosaicistic or no VHL
gene defect in the germ cells. Neuro®bromatosis type 2
(NF2), another dominantly inherited syndrome with a
defective NF2 tumour suppressive gene predisposes to
multiple schwannomas and meningiomas, but the de-
fective NF2 gene is also causative of sporadic schwan-
nomas and meningiomas [13, 19, 29, 43, 44]. In the
schwannoma population, 95% are single and ob-
viously sporadic, 2% are multiple but without classical
NF2, and 3% are related to NF2 (Antinheimo J, un-
published population-based study).
VHL patients have HBs in the brain stem and spinal
cord more often than non-VHL patients [14, 20, 27,
39, 41], which was also con®rmed by our study. Brain
stem and spinal cord locations contribute to the in-
creased management morbidity of HBs in VHL. Vis-
ceral cysts in patients with a single HB of the CNS may
suggest VHL. In our series, however, 13 (14%) HB
patients who were considered as free of VHL had vis-
ceral cysts. Characteristically they had less cysts per
organ and patient than the VHL patients. The occur-
rence of non-VHL cysts in our series corresponds to
that of the general population [5, 18, 23, 48].
Mutation Analysis
In our series, six of the 14 VHL patients had a family
history (43%) for the disease, and eight patients had
apparently a new mutation, a proportion correspond-
ing to the literature [25]. We used direct sequencing of
the VHL gene which is more sensitive than SSCP
(Single Strand Conformation Polymorphism) that de-
tects 50% of VHL mutations [7, 22, 53]. We found a
germ-line mutation in exon 1 in two of the four VHL
patients studied (Case 8: 278 G to C; Case 11: 293 A to
G). Both mutations cause an amino-acid missense
substitution (Gly ± Ala and Tyr ± Cys, respectively),
and are known to be associated with pheochromo-
cytomas which appeared in the family of one VHL
patient [8]. Recent data suggest that with combined
techniques (Southern blotting, ¯uorescence in situ hy-
bridisation, and sequencing of the gene) virtually all
mutation carriers could be identi®ed [46]. The children
of a patient with a VHL gene defect have a risk of 50%
of getting the disease, and they should be o¨ered the
possibility of predictive germ-line mutation testing
to avoid laborious and expensive long-term clinical
screening. It is not possible to predict reliably the se-
verity and spectrum of VHL manifestations based on
any single VHL gene defect [8, 11, 35, 51].
Recurrence of Haemangioblastomas
HB is a slowly growing tumour. There is a general
impression that VHL-associated HBs would grow
faster than sporadic HBs, but this is di½cult to prove
because no volume growth data are available for non-
VHL tumours. Time to recurrence in the original op-
eration area after seemingly complete removal tells
something about the volume growth rate but de novo
tumours may be mistaken for recurrences in VHL pa-
tients. Our series suggests that VHL and non-VHL
HBs grow similarly because the median times to re-
currence were 19 years and 11 years, respectively, and
Long-Term Prognosis of Haemangioblastoma of the CNS 1153
the median MIB indices of 0.3% and 0.2%, respec-
tively, suggest similar low growth potential. In a series
of 27 HBs, without distinction of VHL tumours, the
mean MIB-1 index was 2.8%, higher than in our series,
possibly due to di¨erences in staining and quantitation
protocols [2]. HB is a microsurgically curable tumour
but the risk of late recurrences may be higher than
generally expected. In a previous series of 26 HB pa-
tients operated on between 1974 and 1986, seven pa-
tients developed a recurrence at a mean interval of
seven years after total removal [12]. Recurrences at the
original operation site were detected in 13 of our 84
patients after seemingly complete removal, performed
between 1953 and 1993, and the median time to recur-
rence was considerably longer, 16 years. Also, seven
died of recurrence at a median of 20 years (3±35) after
the primary complete removal. Late recurrences are a
challenge in terms of detection and microsurgery in the
elderly.
Long-Term Survival of VHL Patients
The average life-expectancy of VHL patients is 40 to
50 years [31], 46 years in our series. At present RCC is
the leading cause of death of VHL patients [26], and it
was also a major cause of mortality in our series. In a
recent series of 65 VHL patients with RCC treated by
radical nephrectomy or nephron-sparing surgery, the
RCC speci®c survival rate at ®ve and 10 years was 95
and 77%, respectively, but 23% of the patients devel-
oped end-stage renal failure [45]. Renal transplanta-
tion is an option to treat anephric VHL patients. A
series of 28 patients suggested that immunosuppres-
sion would not enhance the growth of existing tumours
[15]. Further studies with long follow-up are needed to
show whether prolonged immunosuppression increases
the risk of second malignancies in VHL patients with
renal transplants [38]. These aspects are crucial when
deciding whether prophylactic bilateral nephrectomy
with renal transplantation is o¨ered as a life-saving
treatment for VHL patients. Another way to go would
be to develop a speci®c drug therapy against HBs and
RCCs, e.g., relating to angiogenesis in both tumours.
Conclusions
1. The frequency of VHL in patients operated on for
HB(s) of the CNS was 31% before the age of 25
years, 19% between 25 and 45 years, and only 2%
thereafter.
2. In the VHL patients, HB(s) of the CNS were de-
tected at the median age of 33 years, followed by
retinal HBs at 39 years, and RCC at 43 years.
3. Half of the VHL patients had spinal and/or brain
stem HBs at some stage in comparison to only 4±
5% of non-VHL patients.
4. One non-VHL patient had two adjacent HBs in the
same cyst wall.
5. Internal organ cysts in HB patients do not neces-
sarily indicate VHL.
6. The growth rates of non-VHL and VHL-related
HBs were similar as indicated by the median time
to recurrence and the MIB-indices.
7. HB recurrence developed in four of the 10 VHL
patients whose primary surgery was considered to
be radical after a median of 19 years, and in nine of
the 74 non-VHL patients after a median of 11 years.
8. The median length of life of VHL patients was 46
years, with RCC and HBs as equal causes of death.
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Comments
This is an excellent overview on haemangioblastomas of the CNS.
No patient was lost to follow up. Therefore, I would highly recom-
mend this paper for publication. It is a valuable source of informa-
tion for physicians who have to treat and councel patients with hae-
mangioblastomas.
The emphasis on tumours of the abdomen associated with VHL-
Disease is particularly important. Life expectancy of patients with
VHL-Disease was limited by these tumours rather than the CNS
tumour. Therefore, it is important to examine each patient with a
haemangioblastoma for evidence of VHL-Disease. I found it inter-
esting to note that haemangioblastomas of the brain stem and spinal
cord were much more common in VHL-Disease. The higher rate
of tumour recurrence in patients with VHL was also found in our
material.
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